v3.25.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Income Statement [Abstract]        
License Revenue $ 0 $ 0 $ 0 $ 40,560
Operating Expenses        
Research and development 27,610 48,386 54,857 97,971
General and administrative 8,448 16,762 19,028 32,502
Restructuring 0 0 7,796 0
Total operating expenses 36,058 65,148 81,681 130,473
Loss from operations (36,058) (65,148) (81,681) (89,913)
Other Income (Expense)        
Investment and other income (expense), net 9,184 (22,863) 6,528 12,085
Net loss before income taxes (26,874) (88,011) (75,153) (77,828)
Income tax expense 0 266 0 409
Net loss (26,874) (88,277) (75,153) (78,237)
Net loss attributable to noncontrolling interests 0 0 0 (28)
Net loss attributable to Zentalis $ (26,874) $ (88,277) $ (75,153) $ (78,209)
Earnings Per Share        
Net loss per common share outstanding, basic (in dollars per share) $ (0.37) $ (1.24) $ (1.05) $ (1.10)
Net loss per common share outstanding, diluted (in dollars per share) $ (0.37) $ (1.24) $ (1.05) $ (1.10)
Weighted average common shares outstanding        
Weighted average number of common shares outstanding, basic (in shares) 71,992,000 71,040,000 71,836,000 70,969,000
Weighted average number of common shares outstanding, diluted (in shares) 71,992,000 71,040,000 71,836,000 70,969,000